Medisca Recalls Estrone USP Bulk Due to cGMP Deviations
Medisca, Inc. is recalling Estrone, USP Bulk in various bottle sizes due to current Good Manufacturing Practice (cGMP) deviations identified during an FDA inspection.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly identifies the agency classification as Class II. According to the severity rubric, an FDA Class II recall corresponds to a score of 4 (Severe), particularly when associated with manufacturing deficiencies that could impact product quality.
Plain-English summary
Medisca, Inc. has initiated a recall of Estrone, USP Bulk, a pharmaceutical active ingredient (API) product. The recall covers bottles of 100 mgs, 1 gram, 5 grams, 25 grams, and 100 grams, packed by Medisca, Inc. in Plattsburgh, NY. The product is identified by NDC numbers 38779-0891-05, 38779-0891-06, 38779-0891-03, 38779-0891-04, and 38779-0891-09, and Product Code 0891.
The recall was initiated by the manufacturer after deficiencies were noted during a recent FDA inspection. These deficiencies are described as cGMP (current Good Manufacturing Practice) deviations. The FDA has classified this recall as Class II, which indicates a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
The affected product was distributed nationwide as well as in Australia, the Bahamas, Italy, Singapore, Thailand, and the United Kingdom. Specific lot codes are listed in the source data for each bottle size. Consumers and healthcare providers should check their inventory for these specific NDC numbers and lot codes. If the product is found, it should be returned to the supplier or the recalling firm, Medisca, Inc.
The recalled product
- Product
- ESTRONE, USP Bulk, in a) 100 mgs (NDC 38779-0891-05), b) 1 gram (NDC 38779-0891-06), c) 5 grams (NDC 38779-0891-03), d) 25 grams (NDC 38779-0891-04), and e) 100 grams (NDC 38779-0891-09) Bottles, Packed by MEDISCA INC. PLATTSBURGH, NY 12901; Product Code 0891
- Manufacturer
- Medisca, Inc.
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- a) 124880/D
- 124880/O
- 130940/J
- 124880/H
- 124880/M
- 130940/C
- 130940/H
- 135312/C
- 135312/H
- 136546/C d) 124880/A
- 130940/B
- 130940/G
- 135312/B
- 135312/G
- 136546/B
- 139489/A e) 124880/G
- 124880/J
- 124880/L
- 130940/A
- 130940/F
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Medisca, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Medisca, Inc.
See all →- ModerateBimatoprost Bulk Powder Recalled by Medisca for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighBudesonide USP drug ingredient recalled for glass contamination
FDA (Drugs) · 2024-07-10
- SevereMedisca Recalls Estriol USP Micronized Due to Failed Impurity Specifications
FDA (Drugs) · 2019-12-25
- ModerateMedisca Recalls Aminocaproic Acid API Due to CGMP Labeling Deviations
FDA (Drugs) · 2017-09-27
- ModerateMedisca Recalls Estriol USP Bulk Due to cGMP Deviations
FDA (Drugs) · 2017-04-19
Same hazard · cGMP deviation
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateIndomethacin Extended-Release Capsules recalled for cGMP deviations
FDA (Drugs) · 2025-06-11
- SevereLubricant Eye Drops Solution recalled due to sterility assurance concerns
FDA (Drugs) · 2025-05-14